Traws Pharma Stock Performance
| TRAW Stock | 5.02 0.31 5.82% |
The entity has a beta of -0.4, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Traws Pharma are expected to decrease at a much lower rate. During the bear market, Traws Pharma is likely to outperform the market. At this point, Traws Pharma has a negative expected return of -0.5%. Please make sure to validate Traws Pharma's maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Traws Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Traws Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return (8.56) | Five Day Return 3.93 | Year To Date Return (74.58) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:15 | Last Split Date 2021-05-21 |
1 | Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor | 09/30/2024 |
2 | Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment | 10/10/2024 |
3 | Acquisition by Redfield Robert of 97500 shares of Traws Pharma at 0.01 subject to Rule 16b-3 | 10/21/2024 |
4 | Acquisition by Nikolay Savchuk of 885532 shares of Traws Pharma at 0.01 subject to Rule 16b-3 | 11/08/2024 |
5 | Traws Pharma Inc Quarterly 10-Q Report - Quartzy | 11/15/2024 |
| Begin Period Cash Flow | 38.8 M | |
| Free Cash Flow | -17.9 M |
Traws |
Traws Pharma Relative Risk vs. Return Landscape
If you would invest 750.00 in Traws Pharma on September 23, 2024 and sell it today you would lose (248.00) from holding Traws Pharma or give up 33.07% of portfolio value over 90 days. Traws Pharma is currently does not generate positive expected returns and assumes 4.9584% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Traws, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Traws Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Traws Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Traws Pharma, and traders can use it to determine the average amount a Traws Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TRAW |
Estimated Market Risk
| 4.96 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.5 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Traws Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Traws Pharma by adding Traws Pharma to a well-diversified portfolio.
Traws Pharma Fundamentals Growth
Traws Stock prices reflect investors' perceptions of the future prospects and financial health of Traws Pharma, and Traws Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Traws Stock performance.
| Return On Equity | -10.97 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (103.23) % | ||||
| Current Valuation | (8.03 M) | ||||
| Shares Outstanding | 25.31 M | ||||
| Price To Book | 1.67 X | ||||
| Price To Sales | 39.17 X | ||||
| Revenue | 226 K | ||||
| EBITDA | (20.28 M) | ||||
| Net Income | (18.95 M) | ||||
| Total Debt | 12.01 M | ||||
| Book Value Per Share | (4.17) X | ||||
| Cash Flow From Operations | (17.93 M) | ||||
| Earnings Per Share | (5.95) X | ||||
| Market Capitalization | 8.85 M | ||||
| Total Asset | 22.68 M | ||||
| Retained Earnings | (482.63 M) | ||||
| Working Capital | 13.44 M | ||||
About Traws Pharma Performance
Evaluating Traws Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Traws Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Traws Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 12.2 K | 8.5 K | |
| Return On Tangible Assets | (0.84) | (0.88) | |
| Return On Capital Employed | (1.51) | (1.43) | |
| Return On Assets | (0.84) | (0.88) | |
| Return On Equity | (1.78) | (1.86) |
Things to note about Traws Pharma performance evaluation
Checking the ongoing alerts about Traws Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Traws Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Traws Pharma generated a negative expected return over the last 90 days | |
| Traws Pharma has high historical volatility and very poor performance | |
| Traws Pharma has a very high chance of going through financial distress in the upcoming years | |
| Traws Pharma was previously known as Onconova Therapeutics and was traded on NASDAQ Exchange under the symbol ONTX. | |
| The company reported the previous year's revenue of 226 K. Net Loss for the year was (18.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Traws Pharma generates negative cash flow from operations | |
| About 15.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Traws Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Traws Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Traws Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Traws Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Traws Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Traws Pharma's stock. These opinions can provide insight into Traws Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Traws Stock Analysis
When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.